A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment-USMIRC Group - PubMed
4 hours ago
- #multiple myeloma
- #teclistamab
- #renal impairment
- Teclistamab, a BCMA-directed bispecific antibody, was evaluated for efficacy and safety in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI).
- The study included 195 RRMM patients, 34 of whom had baseline RI, showing comparable overall response rates and toxicity profiles between RI and non-RI groups.
- Patients with RI required more packed red blood cell transfusions but had no significant differences in adverse events like cytokine release syndrome or infections.
- Performance status, previous treatment lines, and prior BCMA exposure were significant predictors of progression-free survival.
- The findings support teclistamab's efficacy and safety in RRMM patients with RI, suggesting the need for further prospective trials.